e-Drug3D

2013

FOSDENOPTERIN

INN
FOSDENOPTERIN

cas 150829-29-1

CLASS

METABOLISM
CYCLIC PYRANOPTERIN MONOPHOSPHATE (CPMP)
TREATMENT OF MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
PROVIDES AN EXOGENOUS SOURCE OF CPMP
IS CONVERTED INTO MOLYBDOPTERIN

ROUTE (list)

INTRAVENOUS

NATURAL MOLECULE (link)

ATC code

A16AX19

PK parameters

VD 19.5 LITER (65 KILOGRAM)
Cl 11.7 LITER / HOUR (65 KILOGRAM)
PPB 9 PERCENT
t1/2 1.45 HOUR

Target

DrugCentral

Molybdenum cofactor biosynthesis protein 1 UNIPROT Q9NZB8 MOCS1

Download SDF file

1,3,2-Dioxaphosphorino[4',5':5,6]pyrano[3,2-g]pteridin-10(4H)-one, 8-amino-4a,5a,6,9,11,11a,12,12a-octahydro-2,12,12-trihydroxy-, 2-oxide, (4aR,5aR,11aR,12aS)-

Formula:
C10H14N5O8P

Calculated chemical properties:

MW 362.22
NB_atoms 24
XLogP -3.15
PSA 196.665
NB_HD 7
NB_HA 13
fsp3 0.60
Lipinski(0=no;1=yes) 0

FDA
NDA 214018 (label) INN (FOSDENOPTERIN HYDROBROMIDE) NULIBRY (SENTYNL THERAPS INC) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY